ProfileGDS5678 / 1452360_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 61% 64% 63% 62% 63% 62% 63% 66% 61% 65% 58% 64% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8247763
GSM967853U87-EV human glioblastoma xenograft - Control 23.6557261
GSM967854U87-EV human glioblastoma xenograft - Control 33.8182664
GSM967855U87-EV human glioblastoma xenograft - Control 43.7303263
GSM967856U87-EV human glioblastoma xenograft - Control 53.6418262
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8538763
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8135462
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7700563
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0297466
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.651561
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.901465
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.44358
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8400364
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9888666